ConductScience.org, home

Paper35190830

Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.

Tsuruta A and 6 others. Mol Cancer Res, 2022. Cited by 79 papers, by iCite.

Cite this record

ConductScience Library. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Papers, record 35190830. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35190830

Download JSON
Cell line
RAW 264.7365 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
PubMed
Journal
Mol Cancer Res
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
79
iCite
Relative citation ratio, by iCite
5.07
iCite
Revised in PubMed
2023-01-06
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tsuruta AAkito
2Shiiba YYuki
3Matsunaga NNaoya
4Fujimoto MMarina
5Yoshida YYuyahttps://orcid.org/0000-0003-2394-9748
6Koyanagi SSatoruhttps://orcid.org/0000-0003-4849-2377
7Ohdo SShigehirohttps://orcid.org/0000-0003-4795-9764

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Melanoma, ExperimentalMajor topic
Tumor-Associated MacrophagesMajor topic
Animals
B7-H1 Antigen
Humans
Immune Checkpoint Inhibitors
Mice
NF-kappa B
Programmed Cell Death 1 Receptor
Tumor Microenvironment

Source PubMed

Download CSV of topics

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112354771Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes.J Biol Chem2002https://conductscience.org/library/papers/12354771PubMed
231708917Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion.Front Immunol2019https://conductscience.org/library/papers/31708917PubMed
31396582Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J1992https://conductscience.org/library/papers/1396582PubMed
415824085Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.J Exp Med2005https://conductscience.org/library/papers/15824085PubMed
517082649Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression.J Immunol2006https://conductscience.org/library/papers/17082649PubMed
629735553Optimized Dosing Schedule Based on Circadian Dynamics of Mouse Breast Cancer Stem Cells Improves the Antitumor Effects of Aldehyde Dehydrogenase Inhibitor.Cancer Res2018https://conductscience.org/library/papers/29735553PubMed
731050774Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.JAMA Netw Open2019https://conductscience.org/library/papers/31050774PubMed
829379212NF-κB, inflammation, immunity and cancer: coming of age.Nat Rev Immunol2018https://conductscience.org/library/papers/29379212PubMed
919955445A circadian clock in macrophages controls inflammatory immune responses.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19955445PubMed
1030487606FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells.Nature2018https://conductscience.org/library/papers/30487606PubMed
1128538141Cancer cell and macrophage cross-talk in the tumor microenvironment.Curr Opin Pharmacol2017https://conductscience.org/library/papers/28538141PubMed
1222895791Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22895791PubMed
1322437938Coordinated regulation of myeloid cells by tumours.Nat Rev Immunol2012https://conductscience.org/library/papers/22437938PubMed
1426797126Circadian Clock in a Mouse Colon Tumor Regulates Intracellular Iron Levels to Promote Tumor Progression.J Biol Chem2016https://conductscience.org/library/papers/26797126PubMed
1532726159Out of breath, out of time: interactions between HIF and circadian rhythms.Am J Physiol Cell Physiol2020https://conductscience.org/library/papers/32726159PubMed
1626406148Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015https://conductscience.org/library/papers/26406148PubMed
1732843638The updated landscape of tumor microenvironment and drug repurposing.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32843638PubMed
1830388137Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.PLoS One2018https://conductscience.org/library/papers/30388137PubMed
1927079802Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer2016https://conductscience.org/library/papers/27079802PubMed
2028514441PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.Nature2017https://conductscience.org/library/papers/28514441PubMed

See all 50 referencesDownload CSV of references

Cited by55

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.

PMIDTitleJournalYearIn PapersSource
42928018Roles of macrophages in tumor immunotherapy: metabolism, immune checkpoints, and combination strategies.J Zhejiang Univ Sci B2026https://conductscience.org/library/papers/42928018PubMed
42828155Early time-of-day infusion of PD-1 inhibitor improves prognosis in advanced gastric cancer: a multicenter real-world study.Front Immunol2026https://conductscience.org/library/papers/42828155PubMed
42788839Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.Oncoimmunology2026https://conductscience.org/library/papers/42788839PubMed
42736417Unlocking the clock: a systematic review and meta-analysis on optimizing immune checkpoint inhibitor timing for advanced solid tumors.Br J Cancer2026https://conductscience.org/library/papers/42736417PubMed
42729373
Impact of time-of-day and timing interval of neoadjuvant immunotherapy and chemotherapy infusions among patients with operable NSCLC using the inverse probability of treatment weighting method: a dual-center, retrospective study.
Front Immunol2026https://conductscience.org/library/papers/42729373PubMed
42681659The circadian architecture of tumor immunity: mechanistic insights and treatment strategies.Biomark Res2026https://conductscience.org/library/papers/42681659PubMed
42662830Synchronizing immunity with time: unlocking the potential of chrono-immunotherapy in cancer.Front Immunol2026https://conductscience.org/library/papers/42662830PubMed
42578259Circadian Rhythms in Colorectal Cancer: Recent Advances in Development and Treatment.J Clin Med Res2026https://conductscience.org/library/papers/42578259PubMed
42371094Timing of immune checkpoint inhibitors infusion and prognosis in recurrent/metastatic nasopharyngeal carcinoma: a single-center, retrospective study.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42371094PubMed
42328444Targeting the exosomal CaMK2A-ZDHHC3-GPX4 pathway reprograms tumor-associated macrophages and enhances anti-PD-1/PD-L1 immunotherapy in gastric cancer.Int J Biol Sci2026https://conductscience.org/library/papers/42328444PubMed
42316066Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.BMC Cancer2026https://conductscience.org/library/papers/42316066PubMed
42134900Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.J Immunother Cancer2026https://conductscience.org/library/papers/42134900PubMed
42129307Circadian engineering of in vivo CAR T cell therapy for precision oncology.NPJ Precis Oncol2026https://conductscience.org/library/papers/42129307PubMed
42122266Impact of Blood Type and Administration Timing on Therapeutic Outcomes of Immune Checkpoint Inhibitors for Patients with Lung Cancer in the Chinese Alpine Region.Cancers (Basel)2026https://conductscience.org/library/papers/42122266PubMed
42084869Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.JAMA Netw Open2026https://conductscience.org/library/papers/42084869PubMed
42074080Therapeutic Strategies Targeting the Kidney-Liver-Immune-Heart Network: Circadian and Mechanosensory Pathways in CKD-Associated Cardiac Injury.Int J Mol Sci2026https://conductscience.org/library/papers/42074080PubMed
41929252Hericenone C exhibits anti-nociceptive effects through RORα-mediated suppression of TLR4 transcription.Front Pharmacol2026https://conductscience.org/library/papers/41929252PubMed
41777887Chrono-immunotherapy's current and future optimization strategies: immunotherapy timing in line with the circadian rhythm brings longer survival benefits.Front Immunol2026https://conductscience.org/library/papers/41777887PubMed
41738042Temporal dynamics in cancer immunotherapy: the interplay between circadian rhythms, tumor microenvironment, and immune checkpoint blockade.J Natl Cancer Cent2026https://conductscience.org/library/papers/41738042PubMed
41608568Nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis to enhance macrophage phagocytosis.Theranostics2026https://conductscience.org/library/papers/41608568PubMed

See all 55 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
NFKB14790PubTator's text mininghttps://conductscience.org/library/genes/4790NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35190830

GET https://conductscience.org/api/papers/v1/35190830/references?page=2